Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

202196 citationsJournal Articlebronze Open Access

Authors

Kenneth F. Grossmann · University of Utah

Megan Othus · Data Management (Italy)

Sapna P. Patel · The University of Texas MD Anderson Cancer Center

Ahmad A. Tarhini · Moffitt Cancer Center

Vernon K. Sondak · Moffitt Cancer Center

Michael V. Knopp · Ohio University

Teresa M. Petrella · Sunnybrook Health Science Centre

Thach-Giao Truong

Abstract

Adjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer. See related commentary by Smithy and Shoushtari, p. 599. This article is highlighted in the In This Issue feature, p. 587.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Cutaneous Melanoma Detection and Management Melanoma and MAPK Pathways

Publication Details

Published in: Cancer Discovery

Volume 12, Issue 3, pp. 644-653

DOI: 10.1158/2159-8290.cd-21-1141

Field-Weighted Citation Impact: 5.54

Command Palette

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Authors

Abstract

Topics & Keywords

Publication Details